RxDoctor Payments Data

Michael Ainsworth, MD

Family Medicine · Decatur, INNPI 1629058698

Payments from drug & device makers

$286in general payments, 2019–2025

Across 18 payments — averaging $15.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$159
  • GSK$37
  • Novo Nordisk$29
  • Abbott$24
  • AstraZeneca$15
  • Lilly USA, LLC$13
  • plus $9 from 1 others

What the payments were for

  • Food & beverage$286100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$286 in reported general payments places this provider in the 40th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$99,348
Medicare patients
399
Services billed
1,644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban164$189,467
MounjaroTirzepatide99$125,939
JardianceEmpagliflozin83$113,747
OzempicSemaglutide96$102,725
Avonex (4 Pack)Interferon Beta-1a11$90,924
Trelegy ElliptaFluticasone/Umeclidin/Vilanter97$86,232
JanuviaSitagliptin Phosphate65$81,794
FarxigaDapagliflozin Propanediol50$58,648
XareltoRivaroxaban36$55,489
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog33$34,581
Tresiba Flextouch U-100Insulin Degludec23$28,677
JanumetSitagliptin Phos/Metformin Hcl20$27,550
TrulicityDulaglutide17$27,403
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog29$24,511
Tresiba Flextouch U-200Insulin Degludec11$20,808

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$13$153,342116 claims
Novo NordiskOzempic, Rybelsus$29$119,723107 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$37$115,410163 claims
AstraZenecaFarxiga$15$58,64850 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Decatur

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →